BlossomHill Therapeutics, Inc.
BLSM evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BLSM—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BLSM
BlossomHill Therapeutics, Inc. (BLSM) is a clinical-stage biopharmaceutical company focused on developing precision medicines targeting KRAS mutations using a novel chemical scaffold, with no approved products or revenue to date.
Key risk: Going concern risk
Market Cap
$568.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 1 clinical trial for BlossomHill Therapeutics, Inc..
BlossomHill Therapeutics, Inc. (BLSM) is a clinical-stage biopharmaceutical company focused on developing precision medicines targeting KRAS mutations using a novel chemical scaffold, with no approved products or revenue to date.
- BlossomHill was formed in June 2020 and has a limited operating history, focusing on research and development of product candidates such as BH-501284, BH-30643, and BH-30236 [sec · filed 2026-07-17].
- The company has incurred significant losses, with an accumulated deficit of approximately $156.0 million as of the latest filing [sec · filed 2026-07-17].
- BlossomHill has no product candidates approved for commercial sale and has not generated any revenue from product sales [sec · filed 2026-07-17].
- The company expects to require substantial additional financing to continue its development programs and may face a going concern risk if unable to raise capital [sec · filed 2026-07-17].
- BlossomHill's approach is based on a novel chemical scaffold designed to achieve prolonged, potent, and selective inhibition of KRAS mutations while sparing HRAS and NRAS [sec · filed 2026-07-17].
What works
- BlossomHill's product candidates are designed using a novel chemical scaffold that aims to achieve prolonged, potent, and selective inhibition of KRAS mutations, potentially offering a differentiated approach in a competitive field [sec · filed 2026-07-17].
- The company is advancing multiple programs, including BH-501284 (in IND-enabling studies), BH-30643, and BH-30236, indicating a pipeline with multiple shots on goal [sec · filed 2026-07-17].
- BlossomHill has established an intellectual property portfolio and is scaling up manufacturing processes, which are foundational for future clinical development [sec · filed 2026-07-17].
What to weigh
- BlossomHill has a limited operating history (since June 2020) and has not completed any pivotal or late-stage clinical trials, making it difficult to evaluate its approach and prospects [sec · filed 2026-07-17].
- The company has an accumulated deficit of approximately $156.0 million and expects to continue incurring significant operating losses, with no revenue from product sales [sec · filed 2026-07-17].
- BlossomHill faces substantial capital requirements and a going concern risk; if additional financing is not obtained, it may have to delay, limit, or terminate its development efforts [sec · filed 2026-07-17].
- The company operates in a highly competitive field where competitors may render its approach obsolete through advances in existing or new technologies [sec · filed 2026-07-17].
From the filings
Quoted directly from source documents.
BlossomHill has a limited operating history and no late-stage clinical trial experience.
“We have not completed any pivotal or late-stage clinical trials and we have no history of commercializing products, which may make it difficult to evaluate our approach to the discovery and development of our product candidates and the prospects for our future viability.”
SEC filings · July 17, 2026
The company has an accumulated deficit of approximately $156.0 million.
“an accumulated deficit of approximately $156.0 million.”
SEC filings · July 17, 2026
BlossomHill's product candidates are based on a novel chemical scaffold targeting KRAS mutations.
“which is designed using a novel chemical scaffold to achieve prolonged, potent and selective inhibition of KRAS mutations, but sparing HRAS and NRAS.”
SEC filings · July 17, 2026
The company has no revenue from product sales and expects to need substantial additional financing.
“We have no product candidates approved for commercial sale and have not generated any revenue from the sale of products.”
SEC filings · July 17, 2026
Risks & what to watch (4)›
Key risks
- Going concern risk — The company's independent registered public accounting firm has included a going concern explanatory paragraph, indicating potential inability to continue operations without additional capital [sec · filed 2026-07-17].
- No approved products or revenue — BlossomHill has no approved products and has not generated any revenue from product sales, relying entirely on external financing [sec · filed 2026-07-17].
- Competitive and technological obsolescence — Competitors may render BlossomHill's approach obsolete through advances in existing or new technologies, limiting the commercial value of its product candidates [sec · filed 2026-07-17].
- Dependence on successful clinical trials — The success of product candidates depends on favorable preclinical and clinical results, successful enrollment, and sufficient financial resources, all of which are uncertain [sec · filed 2026-07-17].
What to watch
- Progress of IND-enabling studies for BH-501284 and the timing of any IND submission [sec · filed 2026-07-17].
- Initiation and enrollment of clinical trials for BH-30643 and BH-30236, and any interim or final data readouts [sec · filed 2026-07-17].
- Ability to raise additional capital through equity offerings, collaborations, or licensing deals to extend cash runway beyond current estimates [sec · filed 2026-07-17].
- Any regulatory feedback or milestones from the FDA or other authorities regarding the company's development programs [sec · filed 2026-07-17].
Sources: SEC filings · Generated August 25, 2026 · How we verify sources →
Run BlossomHill Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available BlossomHill Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Frequently asked questions
What is the AI investment thesis for BlossomHill Therapeutics, Inc.?
BlossomHill Therapeutics, Inc. (BLSM) is a clinical-stage biopharmaceutical company focused on developing precision medicines targeting KRAS mutations using a novel chemical scaffold, with no approved products or revenue to date.
Who is the CEO of BlossomHill Therapeutics, Inc.?
Dr. Jingrong Jean Cui Ph.D. is the chief executive officer of BlossomHill Therapeutics, Inc. (BLSM).
Where is BlossomHill Therapeutics, Inc. headquartered?
BlossomHill Therapeutics, Inc. (BLSM) is headquartered in San Diego, CA, United States.
What therapeutic areas does BlossomHill Therapeutics, Inc. focus on?
BlossomHill Therapeutics, Inc. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.